Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 291

Similar articles for PubMed (Select 17636764)

1.

WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Adachi JD, Guyatt G, Papaioannou A, Robinson VA, Shea BJ, Tugwell P, Waldegger LM, Weaver B, Wells G, Zytaruk N.

Cochrane Database Syst Rev. 2007 Jul 18;(1):CD004523. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD004523.

PMID:
17636764
2.

Risedronate for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD, Guyatt G.

Cochrane Database Syst Rev. 2003;(4):CD004523. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD004523.

PMID:
14584020
3.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.

JAMA. 1999 Oct 13;282(14):1344-52.

PMID:
10527181
4.

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004523. doi: 10.1002/14651858.CD004523.pub3. Review.

PMID:
18254053
5.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD005326.

PMID:
16856092
6.

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.

Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.

Endocr Rev. 2002 Aug;23(4):517-23. Review.

PMID:
12202466
7.
8.

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003376. doi: 10.1002/14651858.CD003376.pub3. Review.

PMID:
18254018
9.

WITHDRAWN: Etidronate for treating and preventing postmenopausal osteoporosis.

Cranney A, Adachi JD, Griffith L, Guyatt G, Krolicki N, Robinson VA, Shea BJ, Wells G.

Cochrane Database Syst Rev. 2007 Jul 18;(1):CD003376. Review.

PMID:
17636719
10.

Etidronate for treating and preventing postmenopausal osteoporosis.

Cranney A, Welch V, Adachi JD, Guyatt G, Krolicki N, Griffith L, Shea B, Tugwell P, Wells G.

Cochrane Database Syst Rev. 2001;(4):CD003376. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD003376. Cochrane Database Syst Rev. 2008;(1):CD003376.

PMID:
11687195
11.

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R.

Osteoporos Int. 2000;11(1):83-91.

PMID:
10663363
12.

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis.

Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD, Shea B, Tugwell P, Wells G; Osteoporosis Research Advisory Group (ORAG).

Osteoporos Int. 2001;12(2):140-51.

PMID:
11303715
13.

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.

Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R.

Osteoporos Int. 2012 Jan;23(1):277-84. doi: 10.1007/s00198-011-1574-5. Epub 2011 Mar 2.

PMID:
21365461
14.
15.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005326. Review.

PMID:
17054253
16.

Risedronate for the prevention of fractures in postmenopausal osteoporosis.

Sickels JM, Nip CS.

Ann Pharmacother. 2002 Apr;36(4):664-70. Review.

PMID:
11918518
17.

Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.

Seibel MJ, Naganathan V, Barton I, Grauer A.

J Bone Miner Res. 2004 Feb;19(2):323-9. Epub 2003 Dec 16.

PMID:
14969403
18.

Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.

Adachi JD, Rizzoli R, Boonen S, Li Z, Meredith MP, Chesnut CH 3rd.

Aging Clin Exp Res. 2005 Apr;17(2):150-6.

PMID:
15977464
19.

Bisphosphonates for osteoporosis in people with cystic fibrosis.

Brenckmann C, Papaioannou A.

Cochrane Database Syst Rev. 2001;(4):CD002010. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD002010.

PMID:
11687132
20.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk